Startup entity
market-trends is the sole category represented across all 1 tracked stories. Genmab A/S is most often covered alongside Compass Pathways plc, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 28 original sources each against 5.5 for the same window.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Genmab A/S is most often covered alongside Compass Pathways plc, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 28 original sources each against 5.5 for the same window. The 7 average consequence score is below the beat benchmark of 7.4 in the same window. We currently track 1 Startup story that mention Genmab A/S, all published on February 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab A/S. Shared-story counts are live from our verified record — not editorial picks.
A volatile earnings season is highlighting a sharp divergence in biotech valuations, with Compass Pathways surging on psychedelic therapy success while others face headwinds. Simultaneously, Robinhood's entry into the venture fund IPO market signals a new era of retail access to private-market-style assets.
Genmab A/S is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
